Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy

Modern Pathology

Volumn 25, Issue 3, 2012, Pages 388-397

  Khoury, Thaer ^a   Ademuyiwa, Foluso O ^a   Chandraseekhar, Rameela ^a   Jabbour, Marah ^b   Deleo, Albert ^c   Ferrone, Soldano ^c   Wang, Yangyang ^c   Wang, Xinhui ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b University of Pittsburgh Medical Center ^*

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

ALDH1A1; breast cancer; neoadjuvant

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE1A1; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FISHER EXACT TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR RECURRENCE; TUMOR VOLUME;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84857792056     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.172     Document Type: Article

References (31)

1. Tavassoli FA, Devilee P, (eds) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. IARC Press: Lyon, France, 2003. pp 13.
2. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;17: 747-752.
3. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
4. Honeth G, Bendahl PO, Ringnér M, et al. The CD44 +CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
5. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-226.
6. Buess M, Rajski M, Vogel-Durrer BM, et al. Tumorendothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009;11:987-1002.
7. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
8. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106:13820-13825.
9. Neumeister V, Agarwal S, Bordeaux J, et al. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010;176:2131-2138.
10. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
11. Marcato P, Dean CA, Pan D, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011;29:32-45.
12. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44 +CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005;11:1154-1159.
13. Mylona E, Giannopoulou I, Fasomytakis E, et al. The clinicopathologic and prognostic significance of CD44 +CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008;39: 1096-1102.
14. Aulmann S, Waldburger N, Penzel R, et al. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum Pathol 2010;41:574-581.
15. Nalwoga H, Arnes JB, Wabinga H, et al. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basallike markers and features of aggressive tumours in African breast cancer. Br J Cancer 2010;102:369-375.
16. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010;123:97-108.
17. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009;100:1062-1068.
18. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010;16:45-55.
19. Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003;17:7-23.
20. Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2005;2:138-143.
21. Bunting KD, Townsend AJ. De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anticancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J Biol Chem 1996;271:11884-11890.
22. Moreb JS, Schweder M, Gray B, et al. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther 1998;9:611-619.
23. Canuto RA, Muzio G, Salvo RA, et al. The effect of a novel irreversible inhibitor of aldehyde dehydrogenases 1. and 3 on tumour cell growth and death. Chem Biol Interact 2001;130-132:209-218.
24. Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001;1:167-170.
25. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-4422.
26. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636.
27. Zhou L, Jiang Y, Yan T, et al. The prognostic role of cancer stem cells in breast cancer: a meta-analysis of published literatures. Breast Cancer Res Treat 2010;122:795-801.
28. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15:4234-4241.
29. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
30. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
31. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001344:783-792.